Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia

Ehab Atallah, Jorge Cortes, Susan O'Brien, Sherry Pierce, Mary Beth Rios, Elihu Estey, Maurie Markman, Michael Keating, Emil J. Freireich, Hagop Kantarjian

Research output: Contribution to journalArticle

55 Scopus citations

Abstract

The rates of expected serious adverse events in patients with acute leukemia on chemotherapy far exceed those in patients with solid tumors. Regulatory authorities require similar reporting criteria, which overburden the investigators and infrastructure with unnecessary documentation. To establish a baseline for expected toxicities before and during leukemia therapy, we reviewed 1534 adults with acute myeloid leukemia (AML; excluding acute promyelocytic leukemia) from 1990 to 2006 who received frontline intensive chemotherapy; 723 (47%) were 60 years or older. Prior to therapy, grade 3/4 cytopenias were observed in 86% of patients. All patients developed one or more grade 3/4 cytopenias during therapy, and more than 90% had a febrile episode. Admission to the intensive care unit, mechanical ventilation, and dialysis were required in 28%, 16%, and 7%, respectively. Mortality during induction, 2-week mortality, and 6-week mortality were 20%, 5%, and 16%, respectively. Grade 3/4 renal or hepatic toxicities were observed in 3% and 22% of patients, respectively. Other grade 3 or 4 toxicities were also common before treatment and during therapy. This paper establishes a baseline toxicity rate for patients with AML during induction therapy, and this could be used as a control group for future reference. Guidelines for reporting adverse events in leukemia studies should be revisited.

Original languageEnglish (US)
Pages (from-to)3547-3551
Number of pages5
JournalBlood
Volume110
Issue number10
DOIs
StatePublished - Nov 15 2007
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia'. Together they form a unique fingerprint.

  • Cite this

    Atallah, E., Cortes, J., O'Brien, S., Pierce, S., Rios, M. B., Estey, E., Markman, M., Keating, M., Freireich, E. J., & Kantarjian, H. (2007). Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood, 110(10), 3547-3551. https://doi.org/10.1182/blood-2007-06-095844